Loomis, Sayles & Company
MYGN icon

Loomis, Sayles & Company’s Myriad Genetics MYGN Stock Holding History

Loomis, Sayles & Company’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,189,601
Closed -$60M – 768
2024
Q3 		$60M Buy
2,189,601
+1,326,497
+154% +$35.9M 0.08% 101
2024
Q2 		$21.1M Buy
+863,104
New +$18.9M 0.03% 251
2019
Q2 		– Sell
-475,806
Closed -$15.8M – 683
2019
Q1 		$15.8M Sell
475,806
-26,401
-5% -$804K 0.03% 246
2018
Q4 		$14.6M Buy
502,207
+501,969
+210,911% +$18.1M 0.03% 228
2018
Q3 		$11K Hold
238
– – ﹤0.01% 794
2018
Q2 		$9K Buy
238
+7
+3% +$236 ﹤0.01% 807
2018
Q1 		$7K Sell
231
-922
-80% -$31.2K ﹤0.01% 842
2017
Q4 		$40K Buy
1,153
+395
+52% +$13.3K ﹤0.01% 631
2017
Q3 		$27K Buy
758
+166
+28% +$4.74K ﹤0.01% 710
2017
Q2 		$15K Buy
592
+83
+16% +$1.76K ﹤0.01% 776
2017
Q1 		$10K Hold
509
– – ﹤0.01% 809
2016
Q4 		$8K Buy
509
+33
+7% +$597 ﹤0.01% 858
2016
Q3 		$10K Buy
476
+54
+13% +$1.37K ﹤0.01% 766
2016
Q2 		$13K Buy
422
+126
+43% +$4.38K ﹤0.01% 703
2016
Q1 		$11K Buy
296
+252
+573% +$9.49K ﹤0.01% 811
2015
Q4 		$2K Sell
44
-194
-82% -$8.2K ﹤0.01% 991
2015
Q3 		$9K Buy
+238
New +$8.45K ﹤0.01% 912
2013
Q4 		– Sell
-551,696
Closed -$13M – 783
2013
Q3 		$13M Sell
551,696
-2,997
-0.5% -$85.1K 0.04% 451
2013
Q2 		$14.9K Buy
+554,693
New +$16.1M 0.05% 388

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Loomis, Sayles & Company's MYGN Position: Q4 2024 in Review

Loomis, Sayles & Company sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 2,189,601 shares — an estimated $60M sold.

Loomis, Sayles & Company first reported a position in MYGN in Q2 2013 and held it in 19 quarters. The position peaked at $60M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Loomis, Sayles & Company reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 2,189,601 Myriad Genetics shares in Q4 2024, an estimated $60M.
  • Loomis, Sayles & Company first reported a position in Myriad Genetics in Q2 2013 and held it in 19 quarters.
  • Loomis, Sayles & Company's Myriad Genetics position peaked at $60M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.